Colin J. Dunn, PhD; Nigel D. Stake, PhD; Marilyn M. Hardee, MS
This content is PDF only. Please click on the PDF icon to access.
To the Editor: The results of studies of patients with cancer have shown that significant T-lymphocyte tumor infiltration, increased HLA-DR expression, and tumor regression can be achieved after the infusion of high doses of interleukin-2 and lymphokine-activated killer cells (1, 2). A major concern, however, with this therapy is the incidence of severe side effects (1, 3). One alternative to high-dose cytokine therapy would be the use of a locally implanted polymer, which would allow the slow release of interleukin and the infiltration of a tumor by lymphoid cells without systemic side effects.
We have recently reported (4) a localized
Dunn CJ, Stake ND, Hardee MM. Slow Release of Interleukin-2 from Polymer Implants. Ann Intern Med. 1988;109:761–762. doi: https://doi.org/10.7326/0003-4819-109-9-761_2
Download citation file:
Published: Ann Intern Med. 1988;109(9):761-762.
Copyright © 2020 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use